Submitted by Anonymous (not verified) on 4 December 2023 - 8:47
Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised